Tillkännagivande • Mar 28
Byotrol plc, Annual General Meeting, Apr 22, 2024 Byotrol plc, Annual General Meeting, Apr 22, 2024, at 10:00 Coordinated Universal Time. Location: Riverbank House, 2 Swan Lane, - London United Kingdom Reported Earnings • Dec 09
First half 2024 earnings released: UK£0.002 loss per share (vs UK£0.001 loss in 1H 2023) First half 2024 results: UK£0.002 loss per share (further deteriorated from UK£0.001 loss in 1H 2023). Revenue: UK£2.02m (down 9.4% from 1H 2023). Net loss: UK£742.0k (loss widened 28% from 1H 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 41 percentage points per year, which is a significant difference in performance. Major Estimate Revision • Nov 15
Consensus revenue estimates fall by 13% The consensus outlook for revenues in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from UK£5.40m to UK£4.70m. Forecast losses increased from -UK£0.001 to -UK£0.002 per share. Chemicals industry in the United Kingdom expected to see average net income growth of 10% next year. Consensus price target of UK£0.045 unchanged from last update. Share price fell 32% to UK£0.0065 over the past week. New Risk • Nov 14
New major risk - Revenue and earnings growth Earnings have declined by 14% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 14% per year over the past 5 years. Market cap is less than US$10m (UK£4.09m market cap, or US$5.10m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-UK£1.5m). Currently unprofitable and not forecast to become profitable next year (UK£800k net loss next year). Share price has been volatile over the past 3 months (7.6% average weekly change). Tillkännagivande • Nov 14
Byotrol plc Provides Sales Guidance for the Full Year Ending March 31, 2024 Byotrol plc provided sales guidance for the full year ending March 31, 2024. For the year, the company expects product sales of approximately £3.9 million, which shows modest growth on £3.7 million in the previous year on a like-for-like basis (excluding discontinued items). Including discontinued items, prior year product sales were £4.3 million. New Risk • Nov 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 7.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (UK£3.97m market cap, or US$4.84m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-UK£1.5m). Share price has been volatile over the past 3 months (7.2% average weekly change). Tillkännagivande • Sep 27
Byotrol plc Announces Chief Executive Officer Changes Byotrol plc announced that Vivan Pinto, CEO of the Company, has stepped down as CEO and left the Company to pursue other opportunities. David Traynor formerly Byotrol CEO 2013 - 2022 has kindly agreed to act as interim CEO until a suitable replacement for Vivan is appointed. Tillkännagivande • Sep 08
Byotrol plc Announces the Appointment of Ashley Head to the Board as an Independent Non-Executive Director, with Effect from 13 September 2023 Byotrol plc announced the appointment of Ashley Head to the Board as an independent Non-Executive Director, with effect from AGM on 13 September 2023. Ashley began his career with Chase Manhattan Bank, where he rose through the ranks of technology and online banking. He then joined MasterCard, where he became responsible for the African region of the group. After recognising the opportunities within eCommerce Ashley founded Proc Cyber, growing the business to a valuation of over £60 million in three years and then merging with Datacash in 2006 where he assumed the role of Chairman. Under Ashley's leadership, Datacash grew to a market leading position with MasterCard purchasing the company in 2010. Ashley continues to lead a vibrant portfolio career and currently serves as Chairman of The AI Corporation, MySense Group and Champagne Piaff in addition to other director positions. He is also a trustee for the National Emergency Trust, Epsom College and Stonegate Foundation. Tillkännagivande • Aug 30
Byotrol plc Announces Launch of CHEMGENE MEDLAB into Human Healthcare Byotrol plc announced the launch into human healthcare of its next-generation surface disinfection chemistry, branded CHEMGENE MEDLAB. The CHEMGENE brand, previously marketed by Medimark Scientific Ltd. and acquired by Byotrol in 2018, enjoys a long-standing reputation as a trusted choice for disinfecting surfaces and equipment across emergency services, laboratories, and human health organisations. This new formulation is designed for market-leading, broad-spectrum efficacy, low toxicity and regulatory approval across the UK and EU under the increasingly stringent biocidal regulations. CHEMGENE MEDLAB Multi-Surface Disinfectants are very effective against bacteria, yeasts, fungi, and viruses, with specifically tailored efficacy against: The ESKAPE group of bacteria, targeted in healthcare environments for their multi-drug resistance, and virulence. Critical viruses, including Norovirus, Adenovirus, and the Vaccinia virus-the accepted surrogate for enveloped viruses such as Coronavirus, HIV, Hepatitis B & C, and Herpes Simplex virus. Emerging fungus Candida auris, known for its global health threat due to multi-drug resistance and ease of transmission within healthcare settings. CHEMGENE MEDLAB Multi-Surface Disinfectants are supported by rigorous microbiological testing to the latest European efficacy test methodologies, including stringent medical standards that simulate high soil conditions akin to the presence of blood and other organic fluids during disinfection. Reported Earnings • Jul 31
Full year 2023 earnings released: UK£0.26 loss per share (vs UK£0.003 loss in FY 2022) Full year 2023 results: UK£0.26 loss per share (further deteriorated from UK£0.003 loss in FY 2022). Revenue: UK£4.59m (down 27% from FY 2022). Net loss: UK£1.69m (loss widened 26% from FY 2022). Revenue is expected to fall by 20% p.a. on average during the next 3 years compared to a 5.9% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 144 percentage points per year, which is a significant difference in performance. New Risk • Jun 14
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.9m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£471k net loss next year). Market cap is less than US$100m (UK£8.62m market cap, or US$10.9m). New Risk • Jun 11
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: UK£1.8m Forecast net loss in 1 year: UK£471k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.9m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable next year (UK£471k net loss next year). Market cap is less than US$100m (UK£8.62m market cap, or US$10.8m). Tillkännagivande • May 25
Byotrol plc Announces EPA Approval for Long-Lasting Performance Against Virucidal Claims Byotrol Plc announced that the US Environmental Protection Agency ("EPA") has formally approved long-lasting virucidal claims for its proprietary 24-hour germ-kill surface sanitizer Byotrol 24 (EPA Reg. Number 83614-1). This approval was received by the Company after close of business, on 22 May 2023. The Directors believe that this is the first product to receive such EPA approval and means that Byotrol24 and its sub brands will now be able to offer unique and highly relevant claims and performance characteristics to US consumers and businesses. This includes being able to claim efficacy against certain current and emerging viral pathogens including influenza, coronavirus and norovirus (via the commonly accepted surrogate feline calicivirus). The Company continues to advance alliances and commercial opportunities in the US, including with a previously announced, well-known sub-licensee in the US institutional market, which is continuing to prepare a market launch with the new product claims at the forefront of its marketing strategy. Reported Earnings • Dec 12
First half 2023 earnings released: UK£0.13 loss per share (vs UK£0 in 1H 2022) First half 2023 results: UK£0.13 loss per share (further deteriorated from UK£0 in 1H 2022). Revenue: UK£2.23m (down 30% from 1H 2022). Net loss: UK£579.0k (loss widened 391% from 1H 2022). Revenue is forecast to grow 27% p.a. on average during the next 3 years, while revenues in the Chemicals industry in the United Kingdom are expected to remain flat. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 107 percentage points per year, which is a significant difference in performance. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. CFO & Director Chris Sedwell was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 18
Full year 2022 earnings released Full year 2022 results: Revenue: UK£6.33m (down 44% from FY 2021). Net loss: UK£1.35m (down 238% from profit in FY 2021). Reported Earnings • Aug 31
Full year 2022 earnings released: UK£0.003 loss per share (vs UK£0.002 profit in FY 2021) Full year 2022 results: UK£0.003 loss per share (down from UK£0.002 profit in FY 2021). Revenue: UK£6.33m (down 44% from FY 2021). Net loss: UK£1.35m (down 238% from profit in FY 2021). Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. Price Target Changed • Apr 27
Price target increased to UK£0.11 Up from UK£0.10, the current price target is provided by 1 analyst. New target price is 273% above last closing price of UK£0.029. Stock is down 60% over the past year. The company posted earnings per share of UK£0.0022 last year. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. CFO & Director Chris Sedwell was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 21
Full year 2021 earnings released: EPS UK£0.002 (vs UK£0.001 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: UK£11.2m (up 85% from FY 2020). Net income: UK£979.0k (up 193% from FY 2020). Profit margin: 8.7% (up from 5.5% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 109% per year but the company’s share price has only increased by 10% per year, which means it is significantly lagging earnings growth. Reported Earnings • Dec 11
First half 2021 earnings released: EPS UK£0.002 The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: UK£6.67m (up 207% from 1H 2020). Net income: UK£1.01m (up UK£1.64m from 1H 2020). Profit margin: 15% (up from net loss in 1H 2020). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 104% per year but the company’s share price has only increased by 28% per year, which means it is significantly lagging earnings growth. Reported Earnings • Oct 14
Full year earnings released - EPS UK£0.00077 Over the last 12 months the company has reported total profits of UK£334.0k, down 5.6% from the prior year. Total revenue was UK£6.07m over the last 12 months, up 7.1% from the prior year. Profit margins were 5.5%, which is in line with last year. Analyst Estimate Surprise Post Earnings • Oct 14
Annual earnings released: Revenue and earnings beat expectations Annual revenue exceeded analyst estimates by 1.2% at UK£6.07m. Earnings per share (EPS) also surpassed estimates at UK£0.0008 Revenue is forecast to grow 89% over the next year, compared to a 15% decline forecast for the Chemicals industry in the United Kingdom.